Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 71 entries
Sorted by: Best Match Show Resources per page
"Think of a world without any ... diabetes specialist nurses".

Nursing times

James J.
PMID: 24741878
Nurs Times. 2014 Mar 5-11;110(10):11.

No abstract available.

Cite
James J. "Think of a world without any ... diabetes specialist nurses". Nurs Times. 2014;110(10):11
James, J. (2014). "Think of a world without any ... diabetes specialist nurses". Nursing times, 110(10), 11.
James, June. ""Think of a world without any ... diabetes specialist nurses"." Nursing times vol. 110,10 (2014): 11.
James J. "Think of a world without any ... diabetes specialist nurses". Nurs Times. 2014 Mar 5-11;110(10):11. PMID: 24741878.
Copy Download .nbib Format: NLM
SGLT2 inhibitors enter crowded diabetes space.

Nature biotechnology

Bouchie A.
PMID: 23752410
Nat Biotechnol. 2013 Jun;31(6):469-70. doi: 10.1038/nbt0613-469.

No abstract available.

Cite
Bouchie A. SGLT2 inhibitors enter crowded diabetes space. Nat Biotechnol. 2013;31(6):469-70doi: 10.1038/nbt0613-469.
Bouchie, A. (2013). SGLT2 inhibitors enter crowded diabetes space. Nature biotechnology, 31(6), 469-70. https://doi.org/10.1038/nbt0613-469
Bouchie, Aaron. "SGLT2 inhibitors enter crowded diabetes space." Nature biotechnology vol. 31,6 (2013): 469-70. doi: https://doi.org/10.1038/nbt0613-469
Bouchie A. SGLT2 inhibitors enter crowded diabetes space. Nat Biotechnol. 2013 Jun;31(6):469-70. doi: 10.1038/nbt0613-469. PMID: 23752410.
Copy Download .nbib Format: NLM
Ranting in 2018: Are We Making Progress?.

Diabetes technology & therapeutics

Hirsch IB.
PMID: 29355434
Diabetes Technol Ther. 2018 Feb;20(2):91-93. doi: 10.1089/dia.2018.0004.

No abstract available.

Cite
Hirsch IB. Ranting in 2018: Are We Making Progress?. Diabetes Technol Ther. 2018;20(2):91-93doi: 10.1089/dia.2018.0004.
Hirsch, I. B. (2018). Ranting in 2018: Are We Making Progress?. Diabetes technology & therapeutics, 20(2), 91-93. https://doi.org/10.1089/dia.2018.0004
Hirsch, Irl B. "Ranting in 2018: Are We Making Progress?." Diabetes technology & therapeutics vol. 20,2 (2018): 91-93. doi: https://doi.org/10.1089/dia.2018.0004
Hirsch IB. Ranting in 2018: Are We Making Progress?. Diabetes Technol Ther. 2018 Feb;20(2):91-93. doi: 10.1089/dia.2018.0004. PMID: 29355434.
Copy Download .nbib Format: NLM
[New evidence, new practice: the implications of European and American management guidelines of diabetes mellitus].

Zhonghua nei ke za zhi

Guo YF.
PMID: 32209190
Zhonghua Nei Ke Za Zhi. 2020 Apr 01;59(4):264-266. doi: 10.3760/cma.j.cn112138-20200130-00043.

No abstract available.

Cite
Guo YF. [New evidence, new practice: the implications of European and American management guidelines of diabetes mellitus]. Zhonghua Nei Ke Za Zhi. 2020;59(4):264-266doi: 10.3760/cma.j.cn112138-20200130-00043.
Guo, Y. F. (2020). [New evidence, new practice: the implications of European and American management guidelines of diabetes mellitus]. Zhonghua nei ke za zhi, 59(4), 264-266. https://doi.org/10.3760/cma.j.cn112138-20200130-00043
Guo, Y F. "[New evidence, new practice: the implications of European and American management guidelines of diabetes mellitus]." Zhonghua nei ke za zhi vol. 59,4 (2020): 264-266. doi: https://doi.org/10.3760/cma.j.cn112138-20200130-00043
Guo YF. [New evidence, new practice: the implications of European and American management guidelines of diabetes mellitus]. Zhonghua Nei Ke Za Zhi. 2020 Apr 01;59(4):264-266. doi: 10.3760/cma.j.cn112138-20200130-00043. Chinese. PMID: 32209190.
Copy Download .nbib Format: NLM
Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"?.

Clinical and molecular hepatology

Patoulias D, Doumas M.
PMID: 32971587
Clin Mol Hepatol. 2020 Oct;26(4):582-583. doi: 10.3350/cmh.2020.0264. Epub 2020 Sep 25.

No abstract available.

Cite
Patoulias D, Doumas M. Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"?. Clin Mol Hepatol. 2020;26(4):582-583doi: 10.3350/cmh.2020.0264.
Patoulias, D., & Doumas, M. (2020). Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"?. Clinical and molecular hepatology, 26(4), 582-583. https://doi.org/10.3350/cmh.2020.0264
Patoulias, Dimitrios, and Doumas, Michael. "Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"?." Clinical and molecular hepatology vol. 26,4 (2020): 582-583. doi: https://doi.org/10.3350/cmh.2020.0264
Patoulias D, Doumas M. Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"?. Clin Mol Hepatol. 2020 Oct;26(4):582-583. doi: 10.3350/cmh.2020.0264. Epub 2020 Sep 25. PMID: 32971587; PMCID: PMC7641574.
Copy Download .nbib Format: NLM
Editors' note to Raz and Eldor's commentary "Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms". Diabetes Metab Res Rev 2012.

Diabetes/metabolism research and reviews

Roth J, Pozzilli P.
PMID: 22576779
Diabetes Metab Res Rev. 2012 May;28(4):325. doi: 10.1002/dmrr.2267.

No abstract available.

Cite
Roth J, Pozzilli P. Editors' note to Raz and Eldor's commentary "Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms". Diabetes Metab Res Rev 2012. Diabetes Metab Res Rev. 2012;28(4):325doi: 10.1002/dmrr.2267.
Roth, J., & Pozzilli, P. (2012). Editors' note to Raz and Eldor's commentary "Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms". Diabetes Metab Res Rev 2012. Diabetes/metabolism research and reviews, 28(4), 325. https://doi.org/10.1002/dmrr.2267
Roth, Jesse, and Pozzilli, Paolo. "Editors' note to Raz and Eldor's commentary "Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms". Diabetes Metab Res Rev 2012." Diabetes/metabolism research and reviews vol. 28,4 (2012): 325. doi: https://doi.org/10.1002/dmrr.2267
Roth J, Pozzilli P. Editors' note to Raz and Eldor's commentary "Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms". Diabetes Metab Res Rev 2012. Diabetes Metab Res Rev. 2012 May;28(4):325. doi: 10.1002/dmrr.2267. PMID: 22576779.
Copy Download .nbib Format: NLM
Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis.

The Journal of international medical research

Wu Y, Lu Y, Yang S, Zhang Q.
PMID: 34939442
J Int Med Res. 2021 Dec;49(12):3000605211066306. doi: 10.1177/03000605211066306.

AIM: To assess the effects of incretin-based therapies on β-cell function in patients with type 1 diabetes mellitus (T1DM).METHODS: We searched the PubMed, Cochrane Library, Embase, and Web of Knowledge databases for eligible randomized clinical trials published up to...

Cite
Wu Y, Lu Y, Yang S, et al. Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis. J Int Med Res. 2021;49(12):3000605211066306doi: 10.1177/03000605211066306.
Wu, Y., Lu, Y., Yang, S., & Zhang, Q. (2021). Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis. The Journal of international medical research, 49(12), 3000605211066306. https://doi.org/10.1177/03000605211066306
Wu, Yucheng, et al. "Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis." The Journal of international medical research vol. 49,12 (2021): 3000605211066306. doi: https://doi.org/10.1177/03000605211066306
Wu Y, Lu Y, Yang S, Zhang Q. Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis. J Int Med Res. 2021 Dec;49(12):3000605211066306. doi: 10.1177/03000605211066306. PMID: 34939442.
Copy Download .nbib Format: NLM
The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy.

The lancet. Diabetes & endocrinology

Schmidt TA, Yudkin JS.
PMID: 25702245
Lancet Diabetes Endocrinol. 2015 Mar;3(3):168. doi: 10.1016/S2213-8587(15)00006-6.

No abstract available.

Cite
Schmidt TA, Yudkin JS. The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy. Lancet Diabetes Endocrinol. 2015;3(3):168doi: 10.1016/S2213-8587(15)00006-6.
Schmidt, T. A., & Yudkin, J. S. (2015). The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy. The lancet. Diabetes & endocrinology, 3(3), 168. https://doi.org/10.1016/S2213-8587(15)00006-6
Schmidt, Thomas A, and Yudkin, John S. "The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy." The lancet. Diabetes & endocrinology vol. 3,3 (2015): 168. doi: https://doi.org/10.1016/S2213-8587(15)00006-6
Schmidt TA, Yudkin JS. The Lancet Diabetes & Endocrinology needs a more rigorous conflict of interest policy. Lancet Diabetes Endocrinol. 2015 Mar;3(3):168. doi: 10.1016/S2213-8587(15)00006-6. PMID: 25702245.
Copy Download .nbib Format: NLM
[BZ 55 in the treatment of diabetes].

Revista brasileira de medicina

VIEGAS AP.
PMID: 13466307
Rev Bras Med. 1957 Jul;14(7):467-70.

No abstract available.

Cite
VIEGAS AP. BZ 55 no tratamento da diabetes. [BZ 55 in the treatment of diabetes]. Rev Bras Med. 1957;14(7):467-70
VIEGAS, A. P. (1957). BZ 55 no tratamento da diabetes. [BZ 55 in the treatment of diabetes]. Revista brasileira de medicina, 14(7), 467-70.
VIEGAS, A P. "BZ 55 no tratamento da diabetes." [BZ 55 in the treatment of diabetes]. Revista brasileira de medicina vol. 14,7 (1957): 467-70.
VIEGAS AP. BZ 55 no tratamento da diabetes. [BZ 55 in the treatment of diabetes]. Rev Bras Med. 1957 Jul;14(7):467-70. Portuguese. PMID: 13466307.
Copy Download .nbib Format: NLM
[Permanent success of D 860 therapy].

Deutsche medizinische Wochenschrift (1946)

MOHNIKE G, ULRICH H, JUTZI E.
PMID: 13473483
Dtsch Med Wochenschr. 1957 Sep 06;82(36):1524-5. doi: 10.1055/s-0028-1116922.

No abstract available.

Cite
MOHNIKE G, ULRICH H, JUTZI E. Uber Dauererfolge der D 860-Therapie. [Permanent success of D 860 therapy]. Dtsch Med Wochenschr. 1957;82(36):1524-5doi: 10.1055/s-0028-1116922.
MOHNIKE, G., ULRICH, H., & JUTZI, E. (1957). Uber Dauererfolge der D 860-Therapie. [Permanent success of D 860 therapy]. Deutsche medizinische Wochenschrift (1946), 82(36), 1524-5. https://doi.org/10.1055/s-0028-1116922
MOHNIKE, G, et al. "Uber Dauererfolge der D 860-Therapie." [Permanent success of D 860 therapy]. Deutsche medizinische Wochenschrift (1946) vol. 82,36 (1957): 1524-5. doi: https://doi.org/10.1055/s-0028-1116922
MOHNIKE G, ULRICH H, JUTZI E. Uber Dauererfolge der D 860-Therapie. [Permanent success of D 860 therapy]. Dtsch Med Wochenschr. 1957 Sep 06;82(36):1524-5. doi: 10.1055/s-0028-1116922. German. PMID: 13473483.
Copy Download .nbib Format: NLM
What the patient should be told about the oral hypoglycemic compounds.

Diabetes

DUNCAN GG.
PMID: 13473649
Diabetes. 1957 Nov-Dec;6(6):534-5. doi: 10.2337/diab.6.6.534.

No abstract available.

Cite
DUNCAN GG. What the patient should be told about the oral hypoglycemic compounds. Diabetes. 1957;6(6):534-5doi: 10.2337/diab.6.6.534.
DUNCAN, G. G. (1957). What the patient should be told about the oral hypoglycemic compounds. Diabetes, 6(6), 534-5. https://doi.org/10.2337/diab.6.6.534
DUNCAN, G G. "What the patient should be told about the oral hypoglycemic compounds." Diabetes vol. 6,6 (1957): 534-5. doi: https://doi.org/10.2337/diab.6.6.534
DUNCAN GG. What the patient should be told about the oral hypoglycemic compounds. Diabetes. 1957 Nov-Dec;6(6):534-5. doi: 10.2337/diab.6.6.534. PMID: 13473649.
Copy Download .nbib Format: NLM
[Dosage of sulfanilylbutylcarbamide (BZ 55)].

Gazzetta medica italiana

RAVERA M.
PMID: 13524610
Gazz Med Ital. 1958 Feb;117(2):68-70.

No abstract available.

Cite
RAVERA M. Sul dosaggio della sulfanilbutilcarbamide (BZ 55). [Dosage of sulfanilylbutylcarbamide (BZ 55)]. Gazz Med Ital. 1958;117(2):68-70
RAVERA, M. (1958). Sul dosaggio della sulfanilbutilcarbamide (BZ 55). [Dosage of sulfanilylbutylcarbamide (BZ 55)]. Gazzetta medica italiana, 117(2), 68-70.
RAVERA, M. "Sul dosaggio della sulfanilbutilcarbamide (BZ 55)." [Dosage of sulfanilylbutylcarbamide (BZ 55)]. Gazzetta medica italiana vol. 117,2 (1958): 68-70.
RAVERA M. Sul dosaggio della sulfanilbutilcarbamide (BZ 55). [Dosage of sulfanilylbutylcarbamide (BZ 55)]. Gazz Med Ital. 1958 Feb;117(2):68-70. Italian. PMID: 13524610.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 71 entries